Novartis AG (SWX:NOVN)
Switzerland
· Delayed Price · Currency is CHF 90.91
-0.20 (-0.22%)
May 9, 2025, 5:39 PM CET
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Innovative Medicines | 50.32B |
Log In |
Log In |
Log In |
Log In |
| Innovative Medicines Growth | 11.58% |
Log In |
Log In |
Log In |
Log In |
| Sandoz | - |
Log In |
Log In |
Log In |
Log In |
| Sandoz Growth | - |
Log In |
Log In |
Log In |
Log In |
| Cardiovascular, Renal And Metabolic | 8.58B |
Log In |
Log In |
Log In |
Log In |
| Cardiovascular, Renal And Metabolic Growth | 34.21% |
Log In |
Log In |
Log In |
Log In |
| Immunology | 9.29B |
Log In |
Log In |
Log In |
Log In |
| Immunology Growth | 19.18% |
Log In |
Log In |
Log In |
Log In |
| Neuroscience | 4.75B |
Log In |
Log In |
Log In |
Log In |
| Neuroscience Growth | 30.13% |
Log In |
Log In |
Log In |
Log In |
| Oncology | 14.74B |
Log In |
Log In |
Log In |
Log In |
| Oncology Growth | 14.69% |
Log In |
Log In |
Log In |
Log In |
| Established Brands | 12.96B |
Log In |
Log In |
Log In |
Log In |
| Established Brands Growth | -12.16% |
Log In |
Log In |
Log In |
Log In |
EBIT by Product
Fiscal year is January - December.
Fiscal Year | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|
Period Ending | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Innovative Medicines Operating Profit |
Log In |
Log In |
Log In |
Log In |
| Innovative Medicines Operating Profit Growth |
Log In |
Log In |
Log In |
Log In |
| Sandoz Operating Profit |
Log In |
Log In |
Log In |
Log In |
| Sandoz Operating Profit Growth |
Log In |
Log In |
Log In |
Log In |
| Corporate Operating Profit |
Log In |
Log In |
Log In |
Log In |
| Corporate Operating Profit Growth |
Log In |
Log In |
Log In |
Log In |
Gross Income by Product
Fiscal year is January - December.
Fiscal Year | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|
Period Ending | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Innovative Medicines Gross Profit |
Log In |
Log In |
Log In |
Log In |
| Innovative Medicines Gross Profit Growth |
Log In |
Log In |
Log In |
Log In |
| Sandoz Gross Profit |
Log In |
Log In |
Log In |
Log In |
| Sandoz Gross Profit Growth |
Log In |
Log In |
Log In |
Log In |
| Corporate Gross Profit |
Log In |
Log In |
Log In |
Log In |
| Corporate Gross Profit Growth |
Log In |
Log In |
Log In |
Log In |
Other
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| United States Revenue (Post-Q2 2023 Reporting) | 21.15B |
Log In |
Log In |
Log In |
Log In |
| United States Revenue (Post-Q2 2023 Reporting) Growth | 17.75% |
Log In |
Log In |
Log In |
Log In |
| Europe Revenue (Post-Q2 2023 Reporting) | 15.56B |
Log In |
Log In |
Log In |
Log In |
| Europe Revenue (Post-Q2 2023 Reporting) Growth | 3.73% |
Log In |
Log In |
Log In |
Log In |
| Asia/Africa/Australasia Revenue (Post-Q2 2023 Reporting) | 10.02B |
Log In |
Log In |
Log In |
Log In |
| Asia/Africa/Australasia Revenue (Post-Q2 2023 Reporting) Growth | 7.66% |
Log In |
Log In |
Log In |
Log In |
| Canada and Latin America Revenue (Post-Q2 2023 Reporting) | 3.59B |
Log In |
Log In |
Log In |
Log In |
| Canada and Latin America Revenue (Post-Q2 2023 Reporting) Growth | 13.13% |
Log In |
Log In |
Log In |
Log In |
| Europe Revenue (Pre-Q3 2023 Reporting) | - |
Log In |
Log In |
Log In |
Log In |
| Europe Revenue (Pre-Q3 2023 Reporting) Growth | - |
Log In |
Log In |
Log In |
Log In |
| United States Revenue (Pre-Q3 2023 Reporting) | - |
Log In |
Log In |
Log In |
Log In |
| United States Revenue (Pre-Q3 2023 Reporting) Growth | - |
Log In |
Log In |
Log In |
Log In |
| Asia/Africa/Australasia Revenue (Pre-Q3 2023 Reporting) | - |
Log In |
Log In |
Log In |
Log In |
| Asia/Africa/Australasia Revenue (Pre-Q3 2023 Reporting) Growth | - |
Log In |
Log In |
Log In |
Log In |
| Canada and Latin America Revenue (Pre-Q3 2023 Reporting) | - |
Log In |
Log In |
Log In |
Log In |
| Canada and Latin America Revenue (Pre-Q3 2023 Reporting) Growth | - |
Log In |
Log In |
Log In |
Log In |
| Gilenya Revenue | 552.00M |
Log In |
Log In |
Log In |
Log In |
| Gilenya Revenue Growth | -40.32% |
Log In |
Log In |
Log In |
Log In |
| Tasigna Revenue | 1.67B |
Log In |
Log In |
Log In |
Log In |
| Tasigna Revenue Growth | -9.58% |
Log In |
Log In |
Log In |
Log In |
| Lucentis Revenue | 1.04B |
Log In |
Log In |
Log In |
Log In |
| Lucentis Revenue Growth | -29.22% |
Log In |
Log In |
Log In |
Log In |
| Cosentyx Revenue | 6.14B |
Log In |
Log In |
Log In |
Log In |
| Cosentyx Revenue Growth | 23.31% |
Log In |
Log In |
Log In |
Log In |
| Entresto Revenue | 7.82B |
Log In |
Log In |
Log In |
Log In |
| Entresto Revenue Growth | 29.61% |
Log In |
Log In |
Log In |
Log In |